Thomas H. Kean
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsThomas H. Kean sold $15,001 - $50,000 in $SYK on January 23, 2026 — 19 days before the "Stop Corporate Inversions Act of 2026" (HR7493/S3847) was introduced, a bill aiming to increase tax burdens on companies that have inverted.
Thomas H. Kean sold $15,001 - $50,000 in $JNJ on January 23, 2026 — 41 days before the "Most Favored Patient Act of 2026" (HR7837) was introduced, proposing a most-favored-nation drug pricing model.
Thomas H. Kean sold $1,001 - $15,000 in $GM on January 7, 2026 — 34 days before the 'Safety is Not For Sale Act' (HR7372) advanced, mandating unbundling of safety features in motor vehicles.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $106.09 | $88.09 | -17.0% | Jan 29, 2026 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $15K-$50K | $220.14 | $230.95 | +4.9% | Jan 23, 2026 |
| PARTIAL SELL | $MKL | Markel Group Inc. Common Stock | $15K-$50K | $2,029.21 | $1,845.25 | -9.1% | Jan 23, 2026 |
| PARTIAL SELL | $SYK | Stryker Corporation Common Stock | $15K-$50K | $355.04 | $317.39 | -10.6% | Jan 23, 2026 |
| SELL | $GM | General Motors Company Common Stock | $1K-$15K | $81.91 | $74.40 | -9.2% | Jan 7, 2026 |
| PARTIAL SELL | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | $465.95 | $412.94 | -11.4% | Jan 23, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Safety is Not For Sale Act
The Safety is Not For Sale Act (HR7372) mandates unbundling of optional safety features from convenience/luxury packages in auto sales, directly threatening OEM package revenue. US domestic automakers ($GM, $F, $STLA) face the largest structural risk, with Tesla exposed on ADAS bundling. The bill is in early committee stage (forwarded by subcommittee to full committee by voice vote) and has a long path to enactment, but market data already shows sector weakness.
GAP Supply Act
The GAP Supply Act (HR7528) is an early-stage procedural bill with no funding authorization. It extends a regulatory timeline for compounding facilities during drug shortages but has near-zero near-term market impact. Current real market data shows $VTRS at $15.04 within its 52-week range of $8.19–$16.47, with a +11.32% 30-day gain reflecting broader market trends, not this bill.
SELF DRIVE Act of 2026
The SELF DRIVE Act (HR7390) has advanced out of subcommittee on a strict party-line 12-11 vote, but its path to law is narrow. The bill creates a federal preemption framework for AV safety standards—zero authorized funding. Beneficiary stocks have rallied 5-28% over the last 30 days on anticipation. GOOGL, NVDA, and QCOM are the clearest structural winners due to direct product exposure (Waymo, DRIVE Orin, Snapdragon Ride). INTC's +130% gain is explicitly unrelated to this bill. The 1-vote margin in subcommittee signals that passage through the full Energy & Commerce Committee and the House floor is far from guaranteed.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act (S3847) would retroactively tax inverted companies as domestic corporations, directly hitting MDT, PRGO, and ALLE with $40M to $1.2B in annual tax increases. Market prices already discount this risk: all three are near 52-week lows. The bill is early-stage but has a companion in the House, indicating legislative momentum. Investors holding these names face binary tax-expense risk with limited upside until the bill's path clarifies.
Driver Technology and Pedestrian Safety Act of 2025
HR3360 is a non-binding study bill requiring a DOT-contracted National Academies report on touchscreen driver distractions. It authorizes zero funding, imposes no compliance costs, and has no regulatory or market impact on any public company. Single sponsorship and subcommittee-only status make passage highly unlikely.
PART Act
The PART Act (HR5221) imposes a minor compliance cost of $3–$8/vehicle on new car OEMs to mark catalytic converters with identifying numbers. The bill is early-stage — forwarded to full committee by voice vote in February 2026. For US-traded automakers GM, F, and STLA, the annual cost burden ($5M–$18M each) is immaterial relative to revenue and does not change competitive dynamics. No impact on stock fundamentals.
Motor Vehicle Modernization Act of 2026
The Motor Vehicle Modernization Act of 2026 (HR7389) creates the first statutory definitions for automated driving systems (Levels 3-5) in U.S. law, providing regulatory clarity for autonomous vehicle deployment. The bill has advanced from subcommittee to full committee in the House. Tesla and GM are best positioned given their existing Level 3/4 programs; Ford and Lucid face neutral near-term impact without current Level 3 products. The bill authorizes no direct funding — it is a regulatory modernization bill, not an appropriations bill.
Respect NATO Allies Act
HR7557 (Respect NATO Allies Act) is a procedural early-stage bill requiring Congressional approval before new tariffs on NATO ally imports. It has zero funding, zero direct market mechanism, and is referred to three committees with one cosponsor. Near-zero near-term market impact.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026 (HR7493) is a single-sponsor bill in early committee stage with no near-term market impact. However, Medtronic ($MDT) faces direct structural risk from this bill's retroactive provisions. $MDT is already down 8.17% over 30 days and trading at $79.57, near its 52-week low of $78.91, reflecting broader sector weakness amplified by this legislative overhang.
CMMSA 2.0
HR 7473 (CMMSA 2.0) creates a significant domestic sourcing advantage for US battery materials processors by increasing the Section 45X credit to 25% and imposing a December 2026 ban on prohibited foreign entity materials. $ALB is the primary beneficiary as the largest US lithium processor, while $MP gains via extended critical mineral support for its rare earth and magnet manufacturing. $SQM faces structural headwinds in the US market due to its foreign sourcing position. The bill is early-stage (referred to Ways and Means) but has bipartisan tailwinds from the manufacturing policy agenda.
Other Filings by Thomas H. Kean
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.